A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC.

This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop Grade 3 or higher pneumonitis is ≤10%. The secondary hypothesis of the trial is an overall response rate (ORR) is >50%.

Status:

Recruiting

Phase 2 Icon

Trial Phase

The investigational immunotherapy in combination with chemotherapy and radio therapy is being studied in a group of patients to see if it is safe and effective.

Eligibility

About the Trial

All patients who enroll in the trial will receive medication while on the study.

  • Some participants will receive carboplatin with paclitaxel + pembrolizumab and radiotherapy*
  • Some participants will receive cisplatin with pemetrexed + pembrolizumab and radiotherapy*

* You will be put into one of two groups based on your type of cancer and the chemotherapy combination the study doctor thinks is best for you. 

Trial Purpose
10

US Trial Locations

Clinical trial sites are places such as hospitals or clinics where the trial is being conducted.

See Locations

National Trial Reference Number

NCT03631784 Read More at clinicaltrials.gov

What Can You Do Next?

If you would like to learn about this clinical trial or see if you can participate, you can:

Contact Our Trial Info Center

To learn more, call 1-888-577-8839

Discuss With Your Doctor

Print this page or Email it to your doctor to discuss at your next visit

Tip: To help with understanding of some clinical terms used on the page, select an underlined term to see what they mean.

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Condition

The disease, disorder, syndrome, illness, or injury that is being studied. Conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Non-small Cell Lung Cancer

Age range

18 — no age maximum

Gender(s)

All

Trial Purpose

This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop Grade 3 or higher pneumonitis is ≤10%. The secondary hypothesis of the trial is an overall response rate (ORR) is >50%.

Important information

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

Trial Locations

    Location
    Status
  • Santa Rosa, California, United States, 95403
    Recruiting
  • Fort Wayne, Indiana, United States, 46845
    Recruiting
  • Worcester, Massachusetts, United States, 01655
    Recruiting
  • Detroit, Michigan, United States, 48202
    Recruiting
  • Grand Island, Nebraska, United States, 68803
    Recruiting
  • New Brunswick, New Jersey, United States, 08903
    Recruiting
  • Tulsa, Oklahoma, United States, 74133
    Recruiting
  • Philadelphia, Pennsylvania, United States, 19111
    Recruiting
  • Sioux Falls, South Dakota, United States, 57104
    Recruiting
  • Evanston, Illinois, United States, 60201
    Recruiting

How to Learn More

When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.

Print or email this page.

Trial reference number

A unique identification code given to each clinical trial registered on clinicaltrials.gov.

Keynote number

A unique identification code used by the sponsor to identify a specific trial.
Keynote-799

Official title

A description of the clinical trial that the trial sponsor and clinicians use to identify a specific trial and its purpose.
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).

Call 1-888-577-8839 to contact our trial information center

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.